Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Non-Current Assets (2016 - 2025)

Pediatrix Medical (MD) has disclosed Non-Current Assets for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 1.98% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 billion, a 6.49% decrease, with the full-year FY2025 number at $1.5 billion, down 1.98% from a year prior.
  • Non-Current Assets was $1.5 billion for Q4 2025 at Pediatrix Medical, roughly flat from $1.5 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.9 billion in Q4 2022 to a low of $1.5 billion in Q3 2025.
  • A 5-year average of $1.7 billion and a median of $1.8 billion in 2021 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 212.53% in 2021; the steepest drop was 46.18% in 2021.
  • Pediatrix Medical's Non-Current Assets stood at $1.9 billion in 2021, then increased by 2.01% to $1.9 billion in 2022, then decreased by 9.56% to $1.7 billion in 2023, then dropped by 12.86% to $1.5 billion in 2024, then dropped by 1.98% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MD's Non-Current Assets are $1.5 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.5 billion (Q2 2025).